Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Cited by (1,021)

Items 101–200 of 1,021

1. Tumor Immunotherapy Directed at PD-1
   Antoni Ribas · 2012 · New England Journal of Medicine
2. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
   Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan Gabriel Duda · 2017 · Angiogenesis
3. The secret ally: immunostimulation by anticancer drugs
   Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel, Guido Kroemer · 2012 · Nature Reviews Drug Discovery
4. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
   Daud, Adil I., Wolchok, Jedd D., Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter et al. · 2016 · Journal of Clinical Oncology
5. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
   McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew et al. · 2018 · The Lancet Oncology
6. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
   Gutzmer, Ralf, Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo P, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev et al. · 2020 · The Lancet
7. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
   Masao Hashimoto, Alice Oliffson Kamphorst, Se Jin Im, Haydn Thomas Kissick, Rathi Narayana Pillai, Suresh S. Ramalingam, Koichi Araki, Rafi Ahmed · 2018 · Annual Review of Medicine
8. Toxicities of Immunotherapy for the Practitioner
   Jeffrey S. Weber, James Chih‐Hsin Yang, Michael B. Atkins, Mary Lenora Disis · 2015 · Journal of Clinical Oncology
9. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
   James S. Wilmott, Georgina Venetia Long, Julie R. Howle, Lauren Elaine Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, Richard A. Scolyer · 2011 · Clinical Cancer Research
10. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
11. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
    Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria Isabel Schmidgen, Ralf Gutzmer, Jochen Sven Utikal, Daniela Göppner et al. · 2016 · European Journal of Cancer
12. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
    Johnson, Douglas B., Sullivan, Ryan J., Ott, Patrick A., Carlino, Matteo S., Khushalani, Nikhil I., Ye, Fei, Guminski, Alexander, Puzanov, Igor, Lawrence, Donald P., Buchbinder, Elizabeth I. et al. · 2016 · JAMA Oncology
13. ESMO-magnitude of clinical benefit scale version 1.1
    Cherny, N.I., Dafni, U., Bogaerts, J., Latino, N.J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M.J., de Vries, E.G.E. · 2017 · Annals of Oncology
14. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
    Padmanee Sharma, Klaus Wagner, Jedd D. Wolchok, James Patrick Allison · 2011 · Nature reviews. Cancer
15. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    Ignacio Melero, David M. Berman, Maria Angela Aznar, Alan J. Korman, José Luis Perez‐Gracia, John B.A.G. Haanen · 2015 · Nature reviews. Cancer
16. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
    Rikke Holmgaard, Dmitriy Zamarin, David H. Munn, Jedd D. Wolchok, James Patrick Allison · 2013 · The Journal of Experimental Medicine
17. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
    Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S. Floudas, Parita Soni, Abhinav Binod Chandra · 2017 · Frontiers in Pharmacology
18. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
    Jason Alan Chesney, Igor J. Puzanov, Frances A. Collichio, Parminder Pal Singh, Mohammed M. Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Adam Friedlander, Claus Garbe et al. · 2017 · Journal of Clinical Oncology
19. T cell receptor (TCR) signaling in health and disease
    Kinjal Shah, Amr A. Al-Haidari, Jianmin Sun, Julhash Uddin Kazi · 2021 · Signal Transduction and Targeted Therapy
20. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
    Emily Zhi-Yun Keung, Jeffrey E. Gershenwald · 2018 · Expert Review of Anticancer Therapy
21. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
22. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
    Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saïag, Mark Ross Middleton, Lars Bastholt, Jean‐Jacques Grob, Josep Malvehy, Julia Newton‐Bishop, Alexander Stratigos et al. · 2016 · European Journal of Cancer
23. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
    Martin Reck, Igor Bondarenko, Alexander Valerievich Luft, Piotr Serwatowski, Fabrice Barlési, Raju Titus Chacko, Martin Sebastian, Huiling Lü, Jean-Marie Cuillerot, Thomas James Lynch · 2012 · Annals of Oncology
24. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
    Courtney Davis, Huseyin Naci, Evrim Gurpinar, Elita Poplavska, Ashlyn M. Pinto, Ajay Kumar Aggarwal · 2017 · BMJ
25. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
26. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
    Changyu Wang, Kent B. Thudium, Minhua Han, Xitao Wang, Haichun Huang, Diane Feingersh, Candy Garcia, Yi Ming Wu, Michelle R. Kuhné, Mohan Srinivasan et al. · 2014 · Cancer Immunology Research
27. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
    Romano, Emanuela, Kusio-Kobialka, Monika, Foukas, Periklis G., Baumgaertner, Petra, Meyer, Christiane, Ballabeni, Pierluigi, Michielin, Olivier, Weide, Benjamin, Romero, Pedro, Speiser, Daniel E. · 2015 · Proceedings of the National Academy of Sciences
28. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
29. Deciphering and Reversing Tumor Immune Suppression
    Gregory T. Motz, George Coukos · 2013 · Immunity
30. Cutaneous melanoma: From pathogenesis to therapy (Review)
    Giulia Costanza Leonardi, Luca Falzone, Rossella Salemi, Antonio Zanghì, Demetrios A. Spandidos, James Andrew McCubrey, Saverio Candido, Massimo Libra · 2018 · International Journal of Oncology
31. Bevacizumab plus ipilimumab in patients with metastatic melanoma
    Hodi, F. Stephen, Lawrence, Donald, Lezcano, Cecilia, Wu, Xinqi, Zhou, Jun, Sasada, Tetsuro, Zeng, Wanyong, Giobbie-Hurder, Anita, Atkins, Michael B., Ibrahim, Nageatte et al. · 2014 · Cancer Immunology Research
32. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
    Arce Vargas, Frederick, Furness, Andrew J.S., Litchfield, Kevin, Joshi, Kroopa, Rosenthal, Rachel, Ghorani, Ehsan, Solomon, Isabelle, Lesko, Marta H., Ruef, Nora, Roddie, Claire et al. · 2018 · Cancer Cell
33. Cancer Immunotherapy Comes of Age
    Suzanne Louise Topalian, George J. Weiner, Drew M. Pardoll · 2011 · Journal of Clinical Oncology
34. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
    Picarda, Elodie, Ohaegbulam, Kim C., Zang, Xingxing · 2016 · Clinical Cancer Research
35. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
    Luc Pilotte, Pierre Larrieu, Vincent Stroobant, Didier Colau, Eduard Dolušić, Raphaël Frédérick, Etienne De Plaen, Catherine Uyttenhove, Johan Wouters, Bernard Masereel et al. · 2012 · Proceedings of the National Academy of Sciences
36. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
    Alexander Chan Chi Huang, Roberta Zappasodi · 2022 · Nature Immunology
37. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
    Paul C. Tumeh, Matthew David Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Leticia Loo, Matthew A. Gubens, Michael D. Rosenblum, Christina L. Harview, Janis Marie Taube, Nathan R. Handley et al. · 2017 · Cancer Immunology Research
38. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Evan J. Lipson, Charles G. Drake · 2011 · Clinical Cancer Research
39. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
    Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, Jennifer Tsoi, Lídia Robert, Lucas Goedert, Elaine M. Pinheiro, Richard Chikara Koya, Thomas G. Graeber, Begoña Comı́n-Anduix et al. · 2015 · Science Translational Medicine
40. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
    Igor J. Puzanov, Mohammed M. Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael A. Chastain, Kevin S. Gorski, Abraham Anderson, Jeffrey Chou et al. · 2016 · Journal of Clinical Oncology
41. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
    Leisha A. Emens, Paolo A. Ascierto, Phillip Kevin Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco Maria Marincola · 2017 · European Journal of Cancer
42. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
    Meyer, Christiane, Cagnon, Laurène, Costa-Nunes, Carla M., Baumgaertner, Petra, Montandon, Nicole, Leyvraz, Loredana, Michielin, Olivier, Romano, Emanuela, Speiser, Daniel E. · 2014 · Cancer Immunology Immunotherapy
43. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
    Cheng Xu, Yu‐Pei Chen, Xiao-Jing Du, Jin-Qi Liu, Cheng-Long Huang, Lei Chen, Guan‐Qun Zhou, Wen‐Fei Li, Yan‐Ping Mao, Chiun Hsu et al. · 2018 · BMJ
44. Cutaneous melanoma
    Alexander M.M. Eggermont, Alan Spatz, Caroline Robert · 2013 · The Lancet
45. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Susan F. Slovin, Celestia S. Higano, Omid Hamid, Sheela Tejwani, Andrea Lynne Harzstark, Joshi J. Alumkal, Howard I. Scher, Kevin M. Chin, Paul Gagnier, M. Brent McHenry et al. · 2013 · Annals of Oncology
46. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    Kimberley M. Heinhuis, Willeke Ros, Marleen Kok, Neeltje Steeghs, Jos H. Beijnen, Jan H.M. Schellens · 2019 · Annals of Oncology
47. Translational Implications of Tumor Heterogeneity
    Mariam Jamal‐Hanjani, Sergio A. Quezada, James Larkin, Charles Swanton · 2015 · Clinical Cancer Research
48. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
    Evan J. Lipson, William Howard Sharfman, Charles G. Drake, IRA S. WOLLNER, Janis Marie Taube, Robert A. Anders, Haiying Xu, Sheng Yao, Alice Pons, Lieping Chen et al. · 2012 · Clinical Cancer Research
49. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    Martin Reck, Alexander Valerievich Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-Long Lung Cancer Wu, Christoph Carl Zielinski, Michael Thomas et al. · 2016 · Journal of Clinical Oncology
50. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Foppen, Marnix Geukes, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Romano, Emanuela, Khammari, Amir, Dreno, Brigitte, Capone, Mariaelena et al. · 2016 · Clinical Cancer Research
51. Immune checkpoints and their inhibition in cancer and infectious diseases
    Lydia Dyck, Kingston H. G. Mills · 2017 · European Journal of Immunology
52. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
    Frank Alexander Schildberg, Sarah R. Klein, Gordon James Freeman, Arlene H. Sharpe · 2016 · Immunity
53. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Loi, Sherene, Dushyanthen, Sathana, Beavis, Paul A., Salgado, Roberto, Denkert, Carsten, Savas, Peter, Combs, Susan, Rimm, David L., Giltnane, Jennifer M., Estrada, Monica V. et al. · 2016 · Clinical Cancer Research
54. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey et al. · 2013 · Journal of Clinical Oncology
55. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
    Hamid, Omid, Schmidt, Henrik, Nissan, Aviram, Ridolfi, Laura, Aamdal, Steinar, Hansson, Johan, Guida, Michele, Hyams, David M, Gómez, Henry, Bastholt, Lars et al. · 2011 · Journal of Translational Medicine
56. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
    Milena Perez Mak, Pan Tong, Lixia Diao, Robert J. Cardnell, Don Lynn Gibbons, William N. William, Ferdinandos Skoulidis, Edwin Roger Parra, Jaime Rodriguez‐Canales, Ignacio Ivan Wistuba et al. · 2015 · Clinical Cancer Research
57. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
58. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
    James Larkin, David R. Minor, Sandra P. D’Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. Lao et al. · 2017 · Journal of Clinical Oncology
59. Immune Modulation in Cancer with Antibodies
    David B. Page, Michael A. Postow, Margaret K. Callahan, James Patrick Allison, Jedd D. Wolchok · 2013 · Annual Review of Medicine
60. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
    Coutzac, Clélia, Jouniaux, Jean-Mehdi, Paci, Angelo, Schmidt, Julien, Mallardo, Domenico, Seck, Atmane, Asvatourian, Vahe, Cassard, Lydie, Saulnier, Patrick, Lacroix, Ludovic et al. · 2020 · Nature Communications
61. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
    Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J. · 2016 · Journal for ImmunoTherapy of Cancer
62. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells
    Jian Gu, Jinren Zhou, Qiuyang Chen, Xiaozhang Xu, Ji Gao, Xiangyu Li, Qing Shao, Bo Zhou, Haoming Zhou, Song Wei et al. · 2022 · Cell Reports
63. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Adam Mackiewicz, Vanna Chiarion‐Sileni, Ana Maria Arance, Célèste Lebbé, Lars Bastholt, Omid Hamid, Piotr Lukasz Rutkowski et al. · 2017 · The Lancet Oncology
64. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
    Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Maria Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Lukasz Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà et al. · 2017 · The Lancet Oncology
65. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark Magdi Awad, Patrick Alexander Ott, Raphael Brandão Moreira, Fabio A.B. Schutz, Joaquim Bellmunt B, Guru Sonpavde, Frank Stephen Hodi et al. · 2017 · Cancer Immunology Research
66. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
    Jiang, Xiaofeng, Zhou, Jun, Giobbie-Hurder, Anita, Wargo, Jennifer, Hodi, F. Stephen · 2013 · Clinical Cancer Research
67. Antiemetics: ASCO Guideline Update
    Paul Joseph Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Yowell Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher E.B. Dennis, L. Lee Dupuis, Stacie B. Dusetzina et al. · 2020 · Journal of Clinical Oncology
68. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
    Patrick Hall Lizotte, Amy M. Wen, Mee Rie Sheen, J. Fields, Pakdee Rojanasopondist, Nicole F. Steinmetz, Steven Fiering · 2015 · Nature Nanotechnology
69. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
    Michele Maio, Jean‐Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, Luc Thomas, Claus Garbe, Vanna Chiarion‐Sileni, Alessandro Testori, Tai‐Tsang Chen et al. · 2015 · Journal of Clinical Oncology
70. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
    Peter A. Prieto, James Chih‐Hsin Yang, Richard Mark Sherry, Marybeth S. Hughes, Udai S. Kammula, Donald Edward White, Catherine L. Levy, Steven A. Rosenberg, Giao Q. Phan · 2012 · Clinical Cancer Research
71. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
    Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G. Papavassiliou, Michalis V. Karamouzis · 2020 · World Journal of Gastrointestinal Oncology
72. The inflammatory microenvironment and microbiome in prostate cancer development
    Karen Sandell Sfanos, Srinivasan Yegnasubramanian, William G. Nelson, Angelo Michael De Marzo · 2017 · Nature Reviews Urology
73. Targeting T Cell Co-receptors for Cancer Therapy
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
74. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
    Caroline Voskens, Simone M. Goldinger, Carmen Loquai, Caroline Robert, Katharina C. Kaehler, Carola Berking, Tanja Bergmann, Clemens Luitpold Bockmeyer, Thomas Eigentler, Michael Fluck et al. · 2013 · PLoS ONE
75. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Tuba Nur Gide, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long · 2017 · Clinical Cancer Research
76. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
    Yang Liu, Yinping Dong, Li Kong, Fang Shi, Hui Zhu, Jinming Yu · 2018 · Journal of Hematology & Oncology
77. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
    Yannick Bulliard, Rose Jolicoeur, Maurice Windman, Sarah M. Rue, Seth A. Ettenberg, Deborah A. Knee, Nicholas S. Wilson, Glenn Dranoff, Jennifer L. Brogdon · 2013 · The Journal of Experimental Medicine
78. The immunology of renal cell carcinoma
    Claudia Marcela Diaz-Montero, Brian I. Rini, James Harold Finke · 2020 · Nature Reviews Nephrology
79. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, William Edgar Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan Courtney Fields, Martin D. Fleming et al. · 2019 · Journal of the National Comprehensive Cancer Network
80. Immunotherapy of cancer in 2012
    John M. Kirkwood, Lisa Helene Butterfield, Ahmad A. Tarhini, Hassane M. Zarour, Paweł Kaliński, Soldano Ferrone · 2012 · CA A Cancer Journal for Clinicians
81. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
82. Cancer immunotherapy – revisited
    Willem Joost Lesterhuis, John B.A.G. Haanen, Cornelis J.A. Punt · 2011 · Nature Reviews Drug Discovery
83. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
    Charles G. Drake, Evan J. Lipson, Julie Renee Brahmer · 2013 · Nature Reviews Clinical Oncology
84. PD ‐1 as a potential target in cancer therapy
    David F. McDermott, Michael B. Atkins · 2013 · Cancer Medicine
85. The chemokine system and cancer
    Frances R. Balkwill · 2011 · The Journal of Pathology
86. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
    Jeryl Jean Villadolid, Asim Amin · 2015 · PubMed Central
87. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
    Ross A. Stewart, Michelle Morrow, Scott A. Hammond, Kathy A. Mulgrew, Danielle Marcus, Edmund Poon, Amanda Watkins, Stefanie Mullins, Matthieu Chodorge, John L. Andrews et al. · 2015 · Cancer Immunology Research
88. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
    Sharma, Padmanee, Pachynski, Russell K., Narayan, Vivek, Fléchon, Aude, Gravis, Gwenaelle, Galsky, Matthew D., Mahammedi, Hakim, Patnaik, Akash, Subudhi, Sumit K., Ciprotti, Marika et al. · 2020 · Cancer Cell
89. Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
    Laura C. Cappelli, Anna Kristina Gutierrez, Clifton O. Bingham, Ami A. Shah · 2016 · Arthritis Care & Research
90. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
    Corsello, Salvatore Maria, Barnabei, Agnese, Marchetti, Paolo, De Vecchis, Liana, Salvatori, Roberto, Torino, Francesco · 2013 · The Journal of Clinical Endocrinology & Metabolism
91. Signal pathways of melanoma and targeted therapy
    Weinan Guo, Huina Wang, Chunying Li · 2021 · Signal Transduction and Targeted Therapy
92. Managing Immune Checkpoint-Blocking Antibody Side Effects
    Michael Andrew Postow · 2015 · American Society of Clinical Oncology Educational Book
93. Organoid Models of Tumor Immunology
    Kanako Yuki, Ning Cheng, Michitaka Nakano, Calvin Jay Kuo · 2020 · Trends in Immunology
94. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
    Kevin C. Soares, Agnieszka A. Rucki, Annie A. Wu, Kelly L. Olino, Qian Xiao, Yi Chai, Anthony Wamwea, Elaine O. Bigelow, Eric R. Lutz, Linda L. Liu et al. · 2014 · Journal of Immunotherapy
95. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
    Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou et al. · 2014 · Oncotarget
96. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Reinhard Dummer, Axel Hauschild, Nicole Lindenblatt, George E. Pentheroudakis, Ulrich Keilholz · 2015 · Annals of Oncology
97. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
    Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo, Michele Del Vecchio, Michele Maio, Gian Carlo Antonini Cappellini, Massimo Guidoboni, Paola Queirolo, Paola Savoia, Mario Mandalà et al. · 2016 · Annals of Oncology
98. Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
    Ana P. Kiess, Jedd D. Wolchok, Christopher Andrew Barker, Michael Andrew Postow, Viviane S. Tabar, Jason T. Huse, Timothy An-thy Chan, Yoshiya Josh Yamada, Kathryn P. Beal · 2015 · International Journal of Radiation Oncology*Biology*Physics
99. Elevated cd3+ and cd8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level
    Kmiecik, Justyna, Poli, Aurélie, Brons, Nicolaas H.C., Waha, Andreas, Eide, Geir Egil, Enger, Per Øyvind, Zimmer, Jacques, Chekenya, Martha · 2013 · Journal of Neuroimmunology
100. Combinatorial Strategies for the Induction of Immunogenic Cell Death
     Lucillia Bezu, Lígia Catarina Gomes-da-Silva, Heleen Dewitte, Karine Breckpot, Jitka Palich Fucikova, Radek Špíšek, Lorenzo Galluzzi, Oliver Kepp, Guido Kroemer · 2015 · Frontiers in Immunology